A Study of KF-0210 in Advanced Solid Tumors Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this Phase I, Multi-Center, Open-Label Study is to evaluate the safety,
tolerability, Pharmacokinetics, Pharmacodynamics and anti-tumor activity of KF-0210 in
participants with advanced solid tumors. The study will be conducted in two parts: phase Ia,
and phase Ib.